Johnson & Johnson (JNJ) demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. SPCX
4. IBM
5. ACN
6. NVDA
7. PRIM
8. META
9. SPY
10. TSLA

Go back to Johnson & Johnson (JNJ) demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study
Johnson & Johnson (NYSE: JNJ) Delayed: 234.95 +3.66 (1.58%)
Previous Close $231.29    52 Week High $126.07 
Open $235.64    52 Week Low $94.28 
Day High $237.85    P/E 48.85 
Day Low $234.35    EPS $4.81 
Volume 2,164,126